Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors (Q37908692)

25 August 2017

1 reference

title

Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors (English)

1 reference

25 August 2017

Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

8 December 2024

2

Marie Boyd

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803183

8 December 2024

author name string

Rob J. Mairs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803183

8 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21803183

8 December 2024

publication date

1 September 2011

1 reference

25 August 2017

September 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21803183

full work available at URL

8 December 2024

https://api.elsevier.com/content/article/PII:S0001299811000419?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

https://api.elsevier.com/content/article/PII:S0001299811000419?httpAccept=text/plain

8 December 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Seminars in Nuclear Medicine

8 December 2024

published in

1 reference

25 August 2017

volume

41

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

334-344

1 reference

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

25 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging

8 December 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

8 December 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Malignant Pheochromocytoma in a Population-Based Study: Survival and Clinical Results

8 December 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

8 December 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV

8 December 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma

8 December 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

8 December 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

No-carrier-added synthesis of meta-[131I]iodobenzylguanidine

8 December 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients

8 December 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity

8 December 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells

8 December 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Influence of specific activity on myocardial uptake of 123I-mIBG in rats

8 December 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity.

8 December 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma

8 December 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

8 December 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline

8 December 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine

8 December 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors

8 December 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.

8 December 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment

8 December 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy

8 December 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Two years' experience using no-carrier-added meta-[123I]iodobenzylguanidine in clinical studies

8 December 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

No-carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma

8 December 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Dosimetric aspects of radiolabeled antibodies for tumor therapy

8 December 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes

8 December 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

8 December 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

8 December 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

A kit method for the high level synthesis of [211At]MABG.

8 December 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent

8 December 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions

8 December 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects

8 December 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.

8 December 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.

8 December 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.

8 December 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiation-induced bystander effects: past history and future directions

8 December 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiation-induced bystander effects--implications for cancer.

8 December 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Early events in the apoptotic cascade initiated in cells treated with medium from the progeny of irradiated cells

8 December 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiation-induced genomic instability and bystander effects: related inflammatory-type responses to radiation-induced stress and injury? A review

8 December 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?

8 December 2024

52

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Genomic instability and bystander effects: a historical perspective

8 December 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Tumour therapy with radionuclides: assessment of progress and problems.

8 December 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Free radical-initiated and gap junction-mediated bystander effect due to nonuniform distribution of incorporated radioactivity in a three-dimensional tissue culture model

8 December 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Bystander effect produced by radiolabeled tumor cells in vivo

8 December 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

In vivo validation of the bystander effect

8 December 2024

57

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells

8 December 2024

58

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Relative contribution of bystander and targeted cell killing to the low-dose region of the radiation dose-response curve

8 December 2024

59

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts

8 December 2024

60

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro

8 December 2024

62

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells

8 December 2024

63

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells

8 December 2024

65

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine

8 December 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines

8 December 2024

68

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors

8 December 2024

69

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Topoisomerase I inhibitors: Review and update

8 December 2024

70

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

DNA-topoisomerase I, a new target for the treatment of neuroblastoma

8 December 2024

71

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

8 December 2024

72

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma

8 December 2024

73

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy

8 December 2024

74

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo

8 December 2024

76

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Interaction of ionizing radiation with topotecan in two human tumor cell lines

8 December 2024

78

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation

8 December 2024

79

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination

8 December 2024

81

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

8 December 2024

82

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis

8 December 2024

83

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

8 December 2024

84

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The potential role and application of PARP inhibitors in cancer treatment

8 December 2024

85

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

8 December 2024

86

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models

8 December 2024

87

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

8 December 2024

88

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

8 December 2024

89

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribose)polymerase inhibition - where now?

8 December 2024

90

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target

8 December 2024

91

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase

8 December 2024

92

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

8 December 2024

93

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

8 December 2024

94

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction

8 December 2024

95

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing

8 December 2024

96

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies

8 December 2024

98

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

8 December 2024

100

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

8 December 2024

101

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions

8 December 2024

102

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical perspectives of PARP inhibitors

8 December 2024

103

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

8 December 2024

104

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Development of the proteasome inhibitor PS-341.

8 December 2024

105

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

A phase 2 study of bortezomib in relapsed, refractory myeloma

8 December 2024

106

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

8 December 2024

107

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

8 December 2024

108

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism

8 December 2024

109

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells

8 December 2024

110

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiosensitizing Properties of Bortezomib Depend on Therapeutic Schedule

8 December 2024

111

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

8 December 2024

112

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Persistent oxidative stress in cancer

8 December 2024

113

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis

8 December 2024

114

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Antioxidant enzyme levels in cancer

8 December 2024

115

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Reactive oxygen species: biological stimuli of neuroblastoma cell response

8 December 2024

116

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

PKCδ Sensitizes Neuroblastoma Cells to L-Buthionine-Sulfoximine and Etoposide Inducing Reactive Oxygen Species Overproduction and DNA Damage

8 December 2024

117

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

8 December 2024

118

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Mechanism for the potentiation of oxygen toxicity by disulfiram

8 December 2024

119

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity

8 December 2024

120

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells

8 December 2024

121

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro

8 December 2024

122

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The inhibition of NF-kappaB activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-L-cysteine

8 December 2024

123

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Nuclear factor-kappaB in cancer development and progression

8 December 2024

124

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins

8 December 2024

125

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Disulfiram is a potent in vitro inhibitor of DNA topoisomerases.

8 December 2024

129

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

A concise review of DNA damage checkpoints and repair in mammalian cells

8 December 2024

131

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

8 December 2024

132

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

8 December 2024

133

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration

8 December 2024

134

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

The epigenomics of cancer

8 December 2024

135

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization.

8 December 2024

136

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Anticancer activities of histone deacetylase inhibitors

8 December 2024

137

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

8 December 2024

138

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

8 December 2024

139

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Histone deacetylation as a target for radiosensitization

8 December 2024

140

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Radiosensitization by the histone deacetylase inhibitor PCI-24781.

8 December 2024

141

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

8 December 2024

142

1 reference

https://api.crossref.org/works/10.1053/J.SEMNUCLMED.2011.03.004

8 December 2024

Identifiers

1 reference

25 August 2017

1 reference